ライフサイエンスコーパス: Joseph disease

1 s a promising therapeutic target for Machado-Joseph disease.

2 ng is beneficial in animal models of Machado-Joseph disease.

3 roprotective therapeutic approach in Machado-Joseph disease.

4 causes the neurodegenerative disease Machado-Joseph disease.

5 biquitinating enzyme associated with Machado-Joseph disease.

6 peat (SSR) variation associated with Machado-Joseph disease.

7 torubral-pallidoluysian atrophy, and Machado-Joseph disease.

8 ibuprofen treatment would alleviate Machado-Joseph disease.

9 utant ataxin-3, the genetic cause of Machado-Joseph Disease, also contains an expanded CAG repeat.

10 d longevity in a Drosophila model of Machado-Joseph disease and effectively reduced aggregated ATXN3

11 ially promising therapeutic drug for Machado-Joseph disease and possibly other neurological proteinop

12 polyglutamine disease known both as Machado-Joseph disease and spinocerebellar ataxia type 3.

13 ar ataxia type-3 (SCA3), also called Machado-Joseph disease, and is cleaved in mammalian cells, trans

14 induces neuroprotection, alleviating Machado-Joseph disease-associated neuropathology and motor impai

15 ch correlated with preservation from Machado-Joseph disease-associated neuropathology, namely reducti

16 ebellar ataxia type 3, also known as Machado-Joseph disease, causes dendritic and synapse loss in cul

17 Patients with Machado-Joseph disease exhibit significant motor impairments suc

18 d neurotoxic protein (MJDtr78Q; MJD, Machado-Joseph disease) in the major timeless (tim)-expressing c

19 Machado-Joseph disease is a neurodegenerative disease without ef

20 Machado-Joseph disease is caused by an expansion of a trinucleot

21 g Jews of North African descent, and Machado-Joseph disease is particularly frequent in Yemenite Jews

22 Spinocerebellar ataxia type 3/Machado-Joseph disease is the most common autosomal dominant ata

23 ataxia type 3 (SCA3), also known as Machado-Joseph disease, is reported to be the most common type o

24 eatment of symptomatic patients with Machado-Joseph disease may require cell replacement, which we in

25 ntation into the cerebellum of adult Machado-Joseph disease mice, cerebellar neural stem cells differ

26 ubral pallidoluysian atrophy (DRPLA) Machado-Joseph disease (MJD or SCA3) and SCA2.

27 These include Machado-Joseph disease (MJD) and Huntington's disease (HD), whic

28 Huntington's disease (HD) and Machado Joseph Disease (MJD) are severe neurological disorders t

29 be dysregulated in blood samples of Machado-Joseph disease (MJD) carriers.

30 Strikingly, we find the Machado-Joseph disease (MJD) class to be unappreciated non-lysin

31 Machado-Joseph disease (MJD) is a late-onset, progressive, neuro

32 Machado-Joseph disease (MJD) is a neurodegenerative disorder ass

33 Machado-Joseph disease (MJD) is a neurodegenerative disorder cha

34 Machado-Joseph disease (MJD) is an autosomal dominant neurodegen

35 Machado-Joseph disease (MJD) is an inherited neurodegenerative d

36 Machado-Joseph disease (MJD) is one of at least six neurodegener

37 Machado-Joseph disease (MJD) is the most common dominant autosom

38 The neurodegenerative disease Machado-Joseph disease (MJD), also known as spinocerebellar atax

39 ncy of SCA2 compared with SCA1, SCA3/Machado-Joseph disease (MJD), and dentatorubropallidoluysian atr

40 pinocerebellar ataxia type 1 (SCA1), Machado-Joseph disease (MJD), and Friedreich ataxia.

41 repeat expansion SCAs, such as SCA3/Machado-Joseph disease (MJD), and rare SCAs that are caused by n

42 ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an autosomal-dominant neurodege

43 in patients of Japanese descent with Machado-Joseph disease (MJD), it was reported that disease allel

44 , a deubiquitylase (DUB) involved in Machado-Joseph Disease (MJD), remains elusive.

45 ier of the molecular pathogenesis of Machado-Joseph disease (MJD), the most common autosomal dominant

46 in in the neurodegenerative disorder Machado-Joseph disease (MJD).

47 ches O-GlcNAc to target proteins, in Machado-Joseph disease (MJD).

48 Machado-Joseph disease (MJD; MIM 109150) is a late-onset neurode

49 of 292 spinocerebellar ataxia type 3/Machado-Joseph disease mutation carriers.

50 lts in spinocerebellar ataxia type 3/Machado-Joseph disease, one of the nine polyglutamine neurodegen

51 Machado-Joseph disease or spinocerebellar ataxia 3 (SCA3) is a p

52 Machado-Joseph disease or spinocerebellar ataxia type 3 is an in

53 Additionally, neural cultures of Machado-Joseph disease patients' induced pluripotent stem cells-

54 Spinocerebellar ataxia type 3 (SCA3)/Machado Joseph disease results from expansion of the polyglutami

55 Spinocerebellar ataxia type-3 or Machado-Joseph disease (SCA3/MJD) is a member of the CAG/polyglu

56 bed in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), an autosomal dominant ataxia

57 ebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), is one of at least eight inhe

58 ein in spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), or an unrelated green fluores

59 In spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD), the expanded cytosine adenine

60 ebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease prot

61 Machado-Joseph disease (spinocerebellar ataxia type 3) (prevalen

62 t ataxias was high, particularly for Machado-Joseph disease (spinocerebellar ataxia type 3).

63 that exclusively silenced the mutant Machado-Joseph disease/spinocerebellar ataxia type 3 allele whil

64 del of spinocerebellar ataxia type 3/Machado-Joseph disease that includes a biomarker stage character

65 ent and neuroprotective approach for Machado-Joseph disease therapy.

66 m cells into the cerebellum of adult Machado-Joseph disease transgenic mice and assessed the effect o